Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Clinical Laboratory Tests in SLE

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 526-540

  Quismorio, Francisco P ^a   Torralba, Karina D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942914371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00043-1     Document Type: Chapter

References (97)

1. Slater CA, Davis RB, Shmerling RH Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 1996, 156(13):1421-1425.
2. Meroni PL, Schur PH ANA screening: an old test with new recommendations. Ann Rheum Dis 2010, 69(8):1420-1422.
3. Solomon DH, Kavanaugh AJ, Schur PH Evidence-based guidelines for the use of immunologic tests: Antinucler antibody testing. Arthritis Rheum 2002, 47:434-444. and American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines.
4. Vila LM, Mayor AM, Valentin AH, et al. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 2000, 9:110-115.
5. Steiman AJ, Gladman DD, Ibanez D, et al. Prolonged serologically active clinically quiescent systemic lupus erythematosus. Frequency and outcome. J Rheumatol 2010, 37:1822-1827.
6. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum 2010, 69:1269-1274.
7. Kavanaugh AF, Solomon DH Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests. Arthritis Rheum 2002, 17(5):546-555. and the American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines.
8. Costa MF, Said NR, Zimmermann B Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37(6):381-387.
9. Weinstein A, Bordwell B, Stone B, et al. Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983, 74:206-216.
10. Tozzoli R, Bizzaro N, Tonutti E, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002, 117(2):316-324. Italian Society of Laboratory Medicine Study Group on the Diagnosis of Autoimmune Diseases.
11. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345(8965):1595-1599.
12. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54(11):3623-3632.
13. Liang MH, Simard JF The large print giveth and the small print taketh away: preemptive treatment of serologically active, clinically quiet systemic lupus erythematosus. Arthritis Rheum 2006, 54(11):3378-3380.
14. Benito-Garcia E, Schur PH, Lahita R American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004, 51(6):1030-1044.
15. Arnett FC, Hamilton RG, Roebber MG, et al. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 1988, 15(12):1773-1776.
16. Agarwal S, Harper J, Kiely PD Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009, 18(5):407-412.
17. Frandsen PB, Kriegbaum NJ, Ullman S, et al. Follow-up of 151 patients with high-titer U1RNP antibodies. Clin Rheumatol 1996, 15(3):254-260.
18. Sontheimer RD Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological and genetic findings. Autoimmunity Rev 2005, 4:253-263.
19. Buyon JP, Winchester RJ, Slade SS Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Arthritis Rheum 1993, 36:1263-1273.
20. Pettigrew HD, Teuber SS, Gershwin ME Clinical significance of complement deficiencies. Ann NY Acad Sci 2009, 1173:108-123.
21. Reichlin M ANA negative systemic lupus erythematosus sera revisited serologically. Lupus 2000, 9(2):116-119.
22. Sutej PG, Gear AJ, Morrison RC, et al. Photosensitivity and anti-Ro(SSA) antibodies in black patients with systemic lupus erythematosus. Br J Rheumatol 1989, 28(4):321-324.
23. Cavazzana I, Franceschini F, Belfiore N, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol 2001, 19(4):403-409.
24. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum 2004, 50(3):882-891.
25. Stumvoll GH, Fritsch RD, Meyer B, et al. Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythematosus. Ann Rheum Dis 2009, 68:110-116.
26. Wallace DJ, Lin HC, Shen GQ, et al. Antibodies to histone (H2AH2B)-DNA complexes in the absence of antibodies to double stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 1994, 37:1795-1797.
27. Schett G, Steiner G, Smolen JS Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. Arthritis Rheum 1988, 41:1446-1455.
28. Gómez-Puerta JA, Burlingame RW, Cervera R Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmunity Rev 2008, 7:606-611.
29. Manson JJ, Ma A, Rogers P, et al. Relationship between anti-ds DNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis. A prospective longitudinal study. Arthritis Res Ther 2009, 11(5):R154.
30. Kallenberg CGM Anti-C1q autoantibodies. Autoimmunity Rev 2008, 7:612-615.
31. Matrat A, Veyssetre-Balter C, Trolliet P, et al. Simultaneous detection of anti-C1q and anti-ds DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 2011, 20:28-34.
32. Toubi E, Shoenfeld Y Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmunity Rev 2007, 6:119-125.
33. Barkhudarova F, Dahnrich C, Rosemann A, et al. Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Therapy 2011, 13:R20-R30.
34. Mahler M, Silverman ED, Schulte-Pelkum J, et al. Anti-Scl-70 (topo-1) antibodies in SLE. Myth or reality. Autoimmunity Rev 2010, 9:756-760.
35. Gussin HAE, Ignat GP, Varga J, et al. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44(2):376-383.
36. Respaldiza N, Wichmann I, Ocaña CG, et al. Anti-centromere antibodies in patients with systemic lupus erythematosus. Scand J Rheumatol 2006, 35:290-294.
37. Vila LM, Alarcon GS, McGwin G, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 2005, 32(11):2150-2155.
38. Nasiri S, Karimifar M, Bonakdar ZS, et al. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic. Rheumatol Int 2010, 30(12):1605-1609.
39. Firooz N, Albert DA, Wallace DJ, et al. High sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011, 20:588-597.
40. De Carvalho JF, Hanaoka B, Szyper-Kravitz M, et al. C-reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port 2007, 32(4):317-322.
41. Gaitonde S, Samols D, Kushner I C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008, 59(12):1814-1820.
42. Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005, 14(8):576-582.
43. Bertoli AM, Vila LM, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA):LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008, 35(12):2355-2358. LUMINA Study Group.
44. Lee SS, Singh S, Link K, et al. High-sensitivity c-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008, 38(1):41-54.
45. ter Borg EJ, Horst G, Limburg PC, et al. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990, 17(12):1642-1648.
46. Karadag O, Calguneri M, Atalar E, et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007, 26:695-699.
47. Lee SS, Singh S, Magder LS, et al. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 2008, 17:114-123.
48. Nikpour M, Gladman DD, Ibañez D, et al. Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus 2009, 18:966-973.
49. Meyer O Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine 2010, 77(5):384-389.
50. Shoenfeld Y, Szyper-Kravitz M, Witte T, et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:227-239.
51. Figueredo MA, Rodriguez A, Ruiz-Yagüe M, et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid antibody syndrome. J Rheumatol 2006, 33(10):1980-1986.
52. Bassi N, Ghirardello A, Blank M, et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010, 69:1704-1710.
53. Ho A, Barr SG, Magder LS, et al. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:2350-2357.
54. Birmingham DJ, Irshaid F, Nagaraja HN, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010, 19:1272-1280.
55. Clowse MEB, Magder LS, Petri M The clinical utility of measuring complement and anti-ds DNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011, 38:1012-1016.
56. Liu CC, Manzi S, Kao AH, et al. Cell-bound complement biomarkers for SLE: from benchtop to bedside. Rheum Dis Clin North Am 2010, 36(1):161-172.
57. Sturfelt G, Truedsson Complement and its breakdown products in SLE. Rheumatol 2005, 44:1227-1232.
58. Ogryzlo MA, Maclachlan M, Dauphinee JA, et al. The serum proteins in health and disease; filter paper electrophoresis. Am J Med 1959, 27:596-616.
59. Wallace DJ Serum and plasma protein abnormalities and other clinical laboratory determinations in systemic lupus erythematosus. Dubois' lupus erythematosus 2007, 911-919. Lippincott Williams and Wilkins, Philadelphia, PA. ed 7. D.J. Wallace, B.H. Hahn (Eds.).
60. Yoshizawa S, Nagasawa K, Yoshiaki Y, et al. A thermolabile β2-macroglycoprotein (TMG) and the antibody against TMG in patients with systemic lupus erythematosus. Clin Chim Acta 1997, 264(2):219-225.
61. Ali YM, Urowitz MB, Ibanez D, et al. Monoclonal gammopathy in systemic lupus erythematosus. Lupus 2007, 16:426-429.
62. Yong PFK, Aslam L, Karim MY, et al. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2008, 47:1400-1405.
63. Karim MY Immunodeficiency in the lupus clinic. Lupus 2006, 15:127-131.
64. Levy J, Barnett EV, MacDonald NS, et al. Altered immunoglobulin metabolism in systemic lupus erythematosus and rheumatoid arthritis. J Clin Invest 1970, 49(4):708-715.
65. Lin GG, Li JM IgG subclass serum levels in systemic lupus erythematosus patients. Clin Rheumatol 2009, 28(11):1315-1318.
66. Bijl M, Dijstelbloem HM, Oost WW, et al. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41(1):62-67.
67. Saiki O, Saweki Y, Tanaka T, et al. Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheum 1987, 30:1289-1292.
68. Sivri A, Hasçelik Z IgM deficiency in systemic lupus erythematosus patients. Arthritis Rheum 1995, 38(11):1713.
69. Goldstein MF, Goldstein AL, Dunsky EH, et al. Selective IgM immunodeficiency: retrospective analysis of 36 adult patients with review of the literature. Ann Allergy Asthma Immunol 2006, 97(6):717-730.
70. Monteiro RC The role of IgA and IgA Fc receptors as anti-inflammatory agents. J Clin Immunol 2010, 30(Suppl 1):S61-S64.
71. Mantovani APF, Monclaro MP, Skare TL Prevalence of IgA deficiency in adult systemic lupus erythematosus and the study of the association with its clinical and autoantibody profiles. Bras J Rheumatol 2010, 50(3):273-282.
72. Cassidy JT, Kitson RK, Selby CL Selective IgA deficiency in children and adults with systemic lupus erythematosus. Lupus 2007, 16:647-650.
73. Carneiro-Sampaio M, Liphaus BL, Jesus AA, et al. Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies. J Clin Immunol 2008, 28(Suppl 1):S34-S41.
74. Atta AM, Santiago MB, Guerra FG, et al. Autoimmune response of IgE antibodies to cellular self-antigens in systemic lupus erythematosus. Int Arch Allergy Immunol 2010, 152(4):401-406.
75. North J, Kotecha S, Houtman P, et al. Systemic lupus erythematosus complicating hyper IgE syndrome. Br J Rheumatol 1997, 36(2):297-298.
76. Fernández-Castro M, Mellor-Pita S, Citores MJ, et al. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 2007, 36:238-245.
77. Boccara O, Valeyrie-Allanore L, Crickx B, et al. Association of hypogammaglobulinemia with DRESS (Drug Rash with Eosinophilia and Systemic Symptoms). Eur J Dermatol 2006, 16(6):666-668.
78. Dörner T, Lipsky PE Correlation of circulating CD27 high plasma cells and disease activity in systemic lupus erythematosus. Lupus 2004, 13(5):283-289.
79. Mathian A, Gallegos M, Pascual V, et al. Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice. Eur J Immunol 2011, 41(3):863-872.
80. Estes D, Christian CL The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971, 50:85-96.
81. Shoenfeld Y, Toubi E Protective autoantibodies. Role in homeostasis, clinical importance and therapeutic potentials. Arthritis Rheum 2005, 52:2599-2606.
82. Amezcua-Guerra LM, Springall R, Marquez-Velasco R, et al. Presence of antibodies against cyclic citrullinated peptides in patients with "rhupus": a cross-sectional study. Arthritis Res Ther 2006, 8(5):R144.
83. Quismorio FP, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984, 13(4):349-359.
84. Kakumanu P, Sobel ES, Narain S, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009, 36(12):2682-2690.
85. Qing YF, Zhang QB, Zhou JG, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 2009, 18:713-717.
86. Ferri C Mixed cryoglobulinemia. Orphanet J Rare Dis 2008, 3:25.
87. Cohen RA, Bayliss G, Crispin JC, et al. T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clin Immunol 2008, 128(1):1-7.
88. García-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001, 30(5):366-373.
89. Belizna C, Duijvestijn A, Hamidou M, et al. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis 2006, 65:1545-1550.
90. Domiciano DS, Carvalho JF, Shoenfeld Y Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. Lupus 2009, 18:1233-1238.
91. Bosch X, Guilabert A, Font J Antineutrophil cytoplasmic antibodies. Lancet 2006, 368:404-417.
92. Sen D, Isenberg DA Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2009, 12:651-658.
93. Nasr SH, D'Agati VD, Park H-R, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin Am Soc Nephrol 2008, 3:682-690.
94. Lawson TM, Amos N, Bulgen D, et al. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001, 40:329-335.
95. To CH, Petri M Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus. Arthritis Rheum 2005, 52(12):4003-4010.
96. Tápanes FJ, Vásquez M, Ramirez R, et al. Cluster analysis of antinuclear autoantibodies in the prognosis of SLE nephropathy: are anti-extractable nuclear antibodies protective. Lupus 2000, 9:437-444.
97. Ippolito A, Wallace DJ, Gladman D, et al. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus 2011, 20:250-255.